Head to head

CJC-1295 without DAC vs Ipamorelin

GH secretagogue

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Usually stacked — and Ipamorelin rests on firmer evidence

CJC-1295 without DAC and Ipamorelin appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. If you are picking one, the evidence is the honest tiebreak: Ipamorelin has some human data, but it is small, old, or uncontrolled, while CJC-1295 without DAC has no controlled human data at all, so the numbers here come from practice, not a label. That is a difference in how much is known, not a verdict on how well either works.

What you are actually choosing between

Before anything else: the dataset lists CJC-1295 without DAC and Ipamorelin in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is recovery and sleep, injury repair, and muscle growth. On this site's goal weighting — an editorial priority score, not a measure of effect size — CJC-1295 without DAC rates 4/5 for recovery and sleep and Ipamorelin rates 4/5.

The evidence

This is the part that decides most of it. Ipamorelin has some human data, but it is small, old, or uncontrolled — small early-phase work only; development was discontinued. CJC-1295 without DAC has no controlled human data at all, so the numbers here come from practice, not a label — the closest approved comparators are sermorelin and tesamorelin. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

How they differ in practice

The kinetics are roughly 4× apart — 2 h for Ipamorelin against 30 min for CJC-1295 without DAC — and yet both are dosed once daily. That schedule is convention rather than clearance, which is worth knowing before you assume the two behave the same way between doses.

Risk and difficulty

Ipamorelin is rated beginner here and CJC-1295 without DAC intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

CJC-1295 without DAC (Mod GRF 1-29)

Tetra-substituted GHRH (1-29) with no Drug Affinity Complex, so it clears in roughly 30 minutes and produces a single discrete GH pulse. That short half-life is the whole point: it is dosed once to three times daily, typically around 100 mcg (roughly 1-2 mcg/kg, a saturating pulse dose) on an empty stomach, and is paired with a ghrelin agonist such as ipamorelin. It is NOT an approved medicine; the closest approved comparators are sermorelin and tesamorelin. Consumer supply is research-chemical grade and dosing convention comes from practice, not from a label.

Ipamorelin

Selective ghrelin receptor (GHS-R1a) agonist that triggers a growth hormone pulse with little effect on cortisol or prolactin, which is the main reason it is chosen over hexarelin or GHRP-6. Published human work is limited to small early-phase and post-operative ileus studies; development was discontinued and it is NOT an approved medicine anywhere. Everything sold to consumers is research-chemical grade, so the community 100-300 mcg per dose range comes from practice rather than from a label.

Side by side

The numbers

CJC-1295 without DAC compared with Ipamorelin
Attribute	CJC-1295 without DAC	Ipamorelin
Class	GH secretagogue	GH secretagogue
Routes	Subcutaneous	Subcutaneous
Dose range	100 mcg–300 mcg (typical 100 mcg)	100 mcg–300 mcg (typical 200 mcg)
Frequency	Once daily	Once daily
Half-life	30 min	2 h
Cycle length	12 weeks	12 weeks
Experience	Intermediate	Beginner
Evidence	Practice-derived only	Limited human data
Contraindications	Pregnant / nursing Active malignancy Under 18	Pregnant / nursing Active malignancy Under 18
Side effects	Injection site redness, itching or a short-lived welt Head rush, flushing or warmth in the minutes after injection Mild water retention Tingling or numbness in the hands Drowsiness when dosed pre-bed	Injection site redness or itching Head rush or flushing shortly after injection Water retention and morning puffiness Tingling or numbness in the hands, which can reflect carpal tunnel pressure Vivid dreams or grogginess when dosed pre-bed

Turn a typical dose into a mark on the syringe: CJC-1295 without DACIpamorelin

Goals

Where they overlap, and where they do not

Goal	CJC-1295 without DAC	Ipamorelin
recovery and sleep	CJC-1295 without DAC: 4/5	Ipamorelin: 4/5
injury repair	CJC-1295 without DAC: 3/5	Ipamorelin: 3/5
muscle growth	CJC-1295 without DAC: 3/5	Ipamorelin: 3/5
fat loss	CJC-1295 without DAC: 2/5	Ipamorelin: 2/5
longevity	CJC-1295 without DAC: 2/5	Ipamorelin: 2/5

They overlap on 5 goals and diverge on 0. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographCJC-1295 without DAC (Mod GRF 1-29)Mechanism, protocol, storage, sources.MonographIpamorelinMechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.